Itamar Medical Announces Definitive Agreements for $11.5 Million Private Placement

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Today Itamar Medical Ltd. (TASE: ITMR) announced that it has entered into definitive agreements for a $11.5 million private placement at a purchase price of NIS 1.1693 per ordinary share of the Company, or $9.55 per American Depositary Share (ADSs), each representing 30 ordinary shares. Of the $11.5 million, $8.0 million will be made through purchases of ADSs by U.S. accredited investors (the “U.S. Tranche”), consisting of a fund managed by Deerfield Management Company, L.P. as well as Triple Gate Capital, L.P., West Elk Partners, L.P. and Alpha Capital Anstalt, and the balance of $3.5 million will be by way of issuing ordinary shares to More Investment House. (the “Israeli Tranche”). (The company develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market).

The closing of the transaction is subject to listing and other customary conditions, including (i) with respect to the U.S. Tranche, that (a) the registration statement on Form 20-F filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) under the Securities Exchange Act of 1934 to register the class of ADSs underlying the ADR Program has become effective and (b) the ADSs are eligible for, and have commenced, trading on the Nasdaq Capital Market, and (ii) with respect to the Israeli Tranche, receipt of listing approval by TASE. While the Company expects the closing of the Israeli Tranche to occur within the next several weeks, there is no assurance as to the timing of the closing of the U.S. Tranche in light of, among other things, the continuing federal shutdown in the U.S.

Net proceeds of the financing will be used primarily to accelerate the Company’s revenue growth through direct expansion of its sales and marketing initiatives.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.